Glutathione (IV/IM) vs PNC-27
A side-by-side research comparison of Glutathione (IV/IM) and PNC-27 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Glutathione (IV/IM) | PNC-27 |
|---|---|---|
| Full name | L-Glutathione (Reduced, Injectable) | PNC-27 (p53-Derived Anticancer Peptide) |
| Category | Detox & Antioxidant | Detox & Antioxidant |
| Status | Compounded / Prescription | Research compound (preclinical) |
| Mechanism | Directly conjugates with toxins, heavy metals, and reactive oxygen species via glutathione S-transferases. Regenerates vitamins C and E. Maintains thiol redox status. Supports Phase II liver detoxification. | Contains a p53 domain fused to a membrane-penetrating sequence. It is proposed to bind HDM-2 that is preferentially expressed on cancer cell membranes, forming pores that cause selective necrosis of cancer cells while reportedly sparing normal cells in studies. |
| Molecular weight | 307.32 Da | ~3.2 kDa |
| Half-life | ~2-3 hours (IV bolus) | Short (peptide) |
| Bioavailability | 100% (IV); ~60% (IM); ~5-10% (oral) | Injection (research) |
| Typical dose | 600-2000 mg IV push or 200-600 mg IM | Not established for humans |
| Frequency | 1-3x weekly | Research only |
| Route | Intravenous push or intramuscular injection | Injection (research) |
Glutathione (IV/IM) reported benefits
- Heavy metal detoxification
- Liver support and protection
- Skin brightening/lightening
- Immune system enhancement
- Mitochondrial protection
- Anti-aging (oxidative stress reduction)
PNC-27 reported benefits
- Selective cancer-cell targeting (preclinical)
- p53/HDM-2 mechanism of interest
- Reported sparing of normal cells (studies)
Related comparisons
Research and educational reference only. Not medical advice.